Evotec SE (EVO)

5.27 -0.10 (-1.86%) At close: 04:00PM EDT

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 5,061

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Mario Polywka DPHIL, Ph.D.	CEO & Chairman of the Management Board & Member of the Supervisory Board	N/A	N/A	1963
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	862.66k	N/A	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	763.95k	N/A	1970
Dr. Matthias Evers Ph.D.	Chief Business Officer & Member of Management Board	682.4k	N/A	1973
Ms. Laetitia Rouxel	CFO & Member of Management Board	N/A	N/A	1975
Ms. Anja Bosler	Principal Accounting Officer and Senior Vice President of Group Accounting	N/A	N/A	N/A
Mr. Volker Braun	Executive VP and Head of Global Investor Relations & ESG	N/A	N/A	N/A
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/A	N/A	N/A
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	N/A	N/A	N/A
Dr. Ian M. Hunneyball	Senior Vice President of Programme Management & Clinical Operations	124.46k	N/A	1950

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Corporate Governance

Evotec SE’s ISS Governance QualityScore as of May 1, 2024 is 6. The pillar scores are Audit: 4; Board: 4; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.